The rise of the Coronavirus amongst the humans has led to wide scale health concerns across the globe. What makes this virus particularly potent is its ability to transmit aggressively amongst people leading to pandemic throughout the continents. The World Health Organization recently declared the phenomenon as official pandemic and as such there has been a lot of concern in the medical community regarding the same. One of the best ways to counter and reduce the spread of the COVID-19 disease is effective social distancing that breaks the chain and limits the spread of the virus to specific circles.
The symptoms experienced by patients suffering from COVID-19 are fairly regular and similar to the symptoms when you have the flu. The Coronavirus symptoms include coughing, respiratory issues, difficulty in breathing, head ache and high temperature amongst others. If you feel or experience any of these symptoms then you must get yourself checked immediately in the relevant health care centers.
The recombinant antigens reagents produced by GeneMedi
The recombinant antigens reagents are called by multiple names that include COVID-19 protein Coronavirus protein and COVID-19 antigens. The COVID-19 is essentially a novel category of pathogenic Coronavirus induced disease which first originated in China and subsequently has expanded quickly across the globe.
The GeneMedi is responsible for producing various types of recombinant 2019 nCoV antigens that includes Recombinant Nucleocapsid, Envelope E Protein, 3C like Proteinase, Spike RBD protein, Spike protein – S1 protein and Spike protein (S Protein S1 + S2 ECD). The recombinant proteins related to the Coronavirus such as COVID-19 proteins, 2019 nCOV proteins and Coronavirus proteins were expressed in the types of expression systems like mammalian (human cells, HEK293), baculovirus-insect cells and E-Coli. The recombinant proteins belonging to Coronavirus 2019 or the COVID 19 are apt or appropriate immunogens for the lateral flow tests, functional ELISA and other immunoassays.
You can go to https://www.genemedi.net/ for more details and information on recombinant antigens reagents and services provided by GeneMedi.
Genetic similarity between COVID-19 and SARS-COV
There are some genetics similarity between COVID-19 and the SARS-CoV, also called as SARS2 Coronavirus. The COVID-19 is considered as a novel Coronavirus which is transmitted from the unspecified wild animals and it can lead to (ARD) acute respiratory disease that can have further complicated clinical observations or characteristics. As per genome sequence analysis, the COVID-19 is considered closer to SARS-like bat CoVs (MG772933) than SARS-CoV(8) which descended from the SARS-like bat CoVs. The COVID-19 however share 85% similarity with the SARS-CoV(8) however it has less similarities with the MERS-CoV(9). Within the parameter of high similarity of the RBD in the spike protein there are several analysis which reveal COVID-19 makes use of same receptor as the SARS-COV which is the angiotensin converting enzyme 2 (ACE2) (10-12).In terms of the case fatality rate (CFR) for the COVID-19 and the SARS-CoV, it is affected by multiple factors such as the gender and age.
Conclusions from comparison
Some of the conclusions of the comparison between COVID-19 and SARS-CoV can be found as follows. The older patients are found to have higher Case Fatality Rate (CFR) than the young people. The males have a higher degree of CFR in comparison to the females however this is likely to converge with the increase in age. The COVID-19 infection might eventually show kidney as well as testis damage. This in combination with the higher rate of CFR in the male population, the disorder of the genitourinary system caused by infection of COVID-19 needs proper caution.
It is vital that we should control CRS in the NCP IL-6, IL-10 and their receptors might be potential drugable target. Consistent with the decrease of CD+4 T and the CD+8T cells, the lymphocyte depletion and spleen damage might exist in the NCP patients. The various approaches for T Cell rescued could be considered. The other receptors like DC-Sign and L-Sign must be investigated in future.
About the company
The GeneMedi is one of the best in the industry because it has the established standards of quality control system. The company also has copyrights for 15 software, authorization of 1 patent as well as successful application for the invention of 6 patents and the patents for 6 utility models. In terms of services the GeneMedi provides professional service of packaging technology related to adenovirus, lentivirus and adeno-associated virus (AAV). The different recombinant viral systems of packaging are created for clients.
The GeneMedi has also manufactured and launched a large number of the human full length protein coding ORF cDNA clones in the way of various sets for vector systems that come with multiple features that make the clones fit for numerous functional assays, easy purification in cell types, translation coupling systems and cell free transcription and proteomics study and wide scale functional genomics.